During NAC, according to the Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 [10], the patient developed grade 3 neutropenia, grade 3 anemia, and grade 4 thrombocytopenia, requiring administration of granulocyte colony-stimulating factor (G-CSF) and platelet transfusion. The gene discussed is CSF3; the disease is neutropenia.